Results: Based on planar dose measurements we found that shielding plate attenuates the beam homogenously over its surface. Transmission coefficients for 0.5 cm thick disk were 0.857, 0.875, 0.872 and 0,855 for 4 MeV, 6 MeV, 9 MeV respectively. For 1.0 cm thick plate measured transmission coefficients equaled 0.667, 0.714, 0.737 and 0.739 for 4 MeV, 6 MeV, 9 MeV respectively. Table 1 presents surface dose values for different electron energies with and without bolus cap. The shifts between PDDs with and without bolus cap were estimated as 0.75 cm, 0.40 cm, 0.30 cm and 0.45 cm for 4 MeV, 6 MeV, 9 MeV respectively ( Figure 1 ). The dose increase resulting from backscatter radiation (up to 13.21%, 10.99% and 10.25% for 6 MeV, 9 MeV and 12 MeV respectively) in front of the shielding plate was observed. The dose increase for 4 MeV electron beam energy was negligible. 4 MeV 6 MeV 9 MeV 12 MeV no bolus 84,67% 89,29% 91,35% 92,36% with bolus 98,90% 98,19% 96,06% 93,60% Conclusions: Attenuation of shielding plates was verified and transmission coefficients were calculated. Considerable dose increase in front of the shielding plate was observed for electron beam energies higher than 4 MeV. We observed a significant increase in surface dose, especially for lower electron beam energies. Purpose/Objective: The aim of this work is to evaluate the feasibility of ArcCHECK (AC) and 3DVH v3.1.0 software (SunNuclear Corporation) for QA verification of VMAT patient plans with very small fields, FFF beams, high dose rates and high absorbed doses. We use other traditional QA systems such as Gafchromic EBT3 film, and dose point with a PinPoint (PTW) ionization chamber for comparison as well. Materials and Methods: Four RapidArc plans with very small targets in different body locations and different beam energies were selected: usual head SRS (4.9 cm 3 ) with X6FF beam energy and dose rate up to 600 MU/min, a head SRS (4.9 cm 3 ) with X6FFF and up to 1400 MU/min, a lung SBRT (18.1 cm 3 ) with X6FFF and up to 1400 MU/min in order to deal with heterogeneities and an abdominal SBRT (53.4 cm 3 ) with X10FFF beam energy and dose rate up to 2400 MU/min (maximum dose rate). The 3D dose distributions were calculated by Eclipse with AAA v10.28 algorithm. Measurements were performed in a Varian TrueBeam Linac 2.0. All treatment plans were verified by AC system. Measurements with the diode array were compared with TPS calculations assessed in AC phantom virtual image set with an homogeneous mass density of 1.19 g/cm 3 . 3D gamma analysis was used for the comparison. For EBT3 film and PinPoint measurements, a cylindrical solid water phantom was used. 2D gamma analysis was used to compare film's planar dose distribution with the TPS in the convenient plane of the cylindrical phantom. Seven points were taken into account for chamber measurements in order to assess setup uncertainties, considering a potential setup error of 1 mm in any direction. In the three different systems, measurement to calculation comparisons were evaluated under usual passing rate gamma analysis global and local criteria: 3%/3 mm, 2%/2 mm and 1%/1 mm, dose difference and DTA, with a threshold pf a 10% maximum dose. 3DVH software was also evaluated assessing AC dose measurements inside the patient CT image set and comparing with the TPS calculations. Results: Results for γ-analysis and point dose are shown in table 1.
Results: Based on planar dose measurements we found that shielding plate attenuates the beam homogenously over its surface. Transmission coefficients for 0.5 cm thick disk were 0.857, 0.875, 0.872 and 0,855 for 4 MeV, 6 MeV, 9 MeV respectively. For 1.0 cm thick plate measured transmission coefficients equaled 0.667, 0.714, 0.737 and 0.739 for 4 MeV, 6 MeV, 9 MeV respectively. Table 1 presents surface dose values for different electron energies with and without bolus cap. The shifts between PDDs with and without bolus cap were estimated as 0.75 cm, 0.40 cm, 0.30 cm and 0.45 cm for 4 MeV, 6 MeV, 9 MeV respectively ( Figure 1 ). The dose increase resulting from backscatter radiation (up to 13.21%, 10.99% and 10.25% for 6 MeV, 9 MeV and 12 MeV respectively) in front of the shielding plate was observed. The dose increase for 4 MeV electron beam energy was negligible. Conclusions: Attenuation of shielding plates was verified and transmission coefficients were calculated. Considerable dose increase in front of the shielding plate was observed for electron beam energies higher than 4 MeV. We observed a significant increase in surface dose, especially for lower electron beam energies. Comparing 3DVH results with histograms calculated by TPS, differences around 4-8% on average were found in ICRU 83 parameters for PTV, GTV, ITV and OARs. Conclusions: Global and local gamma passing rate analysis were done for AC and EBT3 film under γ(3%/3 mm), γ(2%/2 mm) and γ(1%/1 mm) criteria. Point dose measurements with PinPoint chamber were also done. Results with film and chamber, used as a gold standard, warrant that AC measurements were in good agreement with TPS calculations. 3DVH has proven to be a good tool to assess dose distribution inside the patient. Thus AC with 3DVH is suitable for clinical use under FFF beams, very small fields, high dose rates and high absorbed doses conditions as long as 4% to 8% differences are considered to be acceptable.
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